Infliximab: lack of efficacy on perforating complications in Crohn's disease (Q47837738)

6 February 2018

title

Infliximab: lack of efficacy on perforating complications in Crohn's disease (English)

1 reference

6 February 2018

2

Walter Reinisch

1 reference

6 February 2018

author name string

Wolfgang Miehsler

1

1 reference

6 February 2018

Lili Kazemi-Shirazi

3

1 reference

6 February 2018

Clemens Dejaco

4

1 reference

6 February 2018

Gottfried Novacek

5

1 reference

6 February 2018

Peter Ferenci

6

1 reference

6 February 2018

Friedrich Herbst

7

1 reference

6 February 2018

Judith Karner

8

1 reference

6 February 2018

Béla Téleky

9

1 reference

6 February 2018

Ewald Schober

10

1 reference

6 February 2018

Harald Vogelsang

11

1 reference

6 February 2018

publication date

1 January 2004

1 reference

6 February 2018

Inflammatory Bowel Diseases

published in

1 reference

6 February 2018

volume

10

1 reference

6 February 2018

issue

1

1 reference

6 February 2018

page(s)

36-40

1 reference

6 February 2018

Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease

cites work

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

Treatment of fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

Remicade does not abolish the need for surgery in fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

Molecular evidence for two forms of Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200401000-00006

10.1097/00054725-200401000-00006

21 January 2018

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

15058525

1 reference

6 February 2018